UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 17, 2012

 

 

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware

(State or other jurisdiction of

incorporation or organization)

 

0-26224

(Commission

File Number)

 

51-0317849

(I.R.S. Employer

Identification No.)

311 Enterprise Drive

Plainsboro, NJ 08536

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (609) 275-0500

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


ITEM 5.07. SUBMISSON OF MATTERS TO A VOTE OF SECURITY HOLDERS

The Annual Meeting of Stockholders of Integra LifeSciences Holdings Corporation (the “Company”) was held on May 17, 2012. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting are as follows:

Item No. 1: All of the Board of Directors’ nominees for director were elected to serve until the Company’s 2013 Annual Meeting or until their respective successors are elected and qualified, by the votes set forth in the table below.

 

Nominees

   For      Against      Abstain      Broker Non-Vote  

Peter J. Arduini

     24,192,838         550,695         8,002         1,004,850   

Thomas J. Baltimore, Jr.

     20,018,779         4,728,119         4,637         1,004,850   

Keith Bradley

     22,498,385         2,248,593         4,557         1,004,850   

Richard E. Caruso

     24,178,874         568,054         4,337         1,005,120   

Stuart M. Essig

     24,164,485         582,946         4,104         1,004,850   

Neal Moszkowski

     22,817,750         1,929,348         4,437         1,004,850   

Raymond G. Murphy

     24,645,576         101,422         4,537         1,004,850   

Christian S. Schade

     24,643,937         102,961         4,637         1,004,850   

James M. Sullivan

     24,245,135         501,793         4,607         1,004,850   

Anne M. VanLent

     24,645,791         101,963         3,781         1,004,850   

Item No. 2: The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2012 fiscal year, by the votes set forth in the table below.

 

For

 

Against

 

Abstain

 

Broker Non-Vote

25,331,929

  418,512   5,944   0

Item No. 3: The stockholders approved, on an advisory, non-binding basis, the compensation of certain executive officers, by the votes set forth in the table below.

 

For

 

Against

 

Abstain

 

Broker Non-Vote

12,544,402

  12,187,632   19,501   1,004,850


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date: May 18, 2012     By:  

/s/ John B. Henneman, III

      John B. Henneman, III
    Title:  

Executive Vice President,

Finance and Administration,

and Chief Financial Officer